glp-1 drugs and alzheimer's Drug Fails to Quell in Novo Nordisk Trials Could diabetes and weight loss

Description

So researchers looked at the medical records of more than 3,000 people with hormone receptor-positive DCIS on hormonal therapy and GLP-1s, as well as an equal number of people with hormone receptor-positive DCIS who were not taking GLP-1s

Patients who accept obesity as a chronic condition requiring ongoing management maintain weight loss successfully and report high satisfaction with outcomes

Conversely, the LIRAFLAME trial failed to show a significant effect of liraglutide compared to placebo on vascular inflammation as assessed by [18F]FDG PET after 26 weeks of treatment in people with T2DM [140]

Similarily, GLP-1R-mediated suppression of NF-B p65 was also able to modulate neuropathic pain-induced neuroinflammation and improve recognition memory dysfunction (64)